Mangoceuticals (NASDAQ:MGRX – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.19) EPS for the quarter, FiscalAI reports. The business had revenue of $0.07 million for the quarter. Mangoceuticals had a negative return on equity of 96.39% and a negative net margin of 4,794.60%.
Mangoceuticals Stock Down 1.4%
MGRX stock traded down $0.00 during trading on Tuesday, reaching $0.16. The stock had a trading volume of 214,241 shares, compared to its average volume of 7,673,559. The company’s 50 day moving average is $0.34 and its two-hundred day moving average is $0.39. The company has a market capitalization of $3.41 million, a price-to-earnings ratio of -0.16 and a beta of 2.15. Mangoceuticals has a one year low of $0.15 and a one year high of $1.38.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Mangoceuticals in a report on Monday, September 21st. Wall Street Zen raised Mangoceuticals to a “sell” rating in a research note on Saturday, July 25th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has an average rating of “Sell”.
Get Our Latest Analysis on MGRX
Mangoceuticals Company Profile
Mangoceuticals, Inc. is a men’s health and wellness company that offers telehealth services through its online platform. The platform connects customers with healthcare providers for consultations and, when appropriate, prescription treatments. The company’s offerings have included treatments for erectile dysfunction, hair loss and testosterone-related concerns, as well as weight-management services. Prescriptions are fulfilled through pharmacy partners. Mangoceuticals primarily serves customers in the United States through its digital platform.
Read More
- Five stocks we like better than Mangoceuticals
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
